Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: An active regimen with limiting neurotoxicity

Journal of Clinical Oncology

Volumn 14, Issue 7, 1996, Pages 1993-1999

  Wasserheit, C ^a   Frazein, A ^a   Oratz, R ^a   Sorich, J ^a   Downey, A ^a   Hochster, H ^a   Chachoua, A ^a   Wernz, J ^a   Zeleniuch Jacquotte, A ^a   Blum, R ^a   Speyer, J ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 8944253777     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.7.1993     Document Type: Article

References (28)

1. Henderson IC: Chemotherapy for advanced disease, in Harris JR, Hellman S, Henderson IC, et al (eds): Breast Diseases. Philadelphia, PA, Lippincott, 1987, pp 428-479
2. Hortabagyi G, Bodey G, Buzdar A, et al: Evaluation of High dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: A prospective randomized study. J Clin Oncol 5:354-364, 1987
3. Beveridge R, Abeloff M, Donehower R, et al: Sixteen week dose intense therapy for breast cancer. Proc Am Soc Clin Oncol 7:47, 1988 (abstr)
4. Peters W, Ross M, Vredenburgh J, et al: High-dose alkylating agents and autologous bone marrow support for stage II/III breast cancer involving 10 or more axillary nodes. Proc Am Soc Clin Oncol 11:59, 1992 (abstr)
5. Kolaric K, Roth A: Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 11:108-112, 1983
6. Sledge G, Sr PL, Roth B, et al: Cisplatin as first line therapy for metastatic breast cancer. J Clin Oncol 6:1811-1814, 1988
7. Cocconi G, Bisagni G, Lise VD, et al: Platinum and etoposide as first line therapy in metastatic breast cancer. Proc Am Soc Clin Oncol 7:48, 1988 (abstr)
8. Theriault R, Hortobagyi G, Kau S, et al: Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin and cyclophosphamide in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 7:141, 1988 (abstr)
9. Rowinsky E, Cazenave L, Donehower R: Taxol: A novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247-1259, 1990
10. Holmes F, Valero V, Walters R, et al: The M.D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. Monogr J Natl Cancer Inst 15:161-169, 1993
11. Murphy Wk, Fossella FV, Winn RJ, et al: Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 85:384-388, 1993
12. Forastiere A: Use of paclitaxel in squamous cell carcinoma of the head and neck. Semin Oncol 20:56-60, 1993 (suppl 3)
13. Saville MW, Lietzau J, Wilson W, et al: A trial of paclitaxel in patients with HIV-associated Kaposi's sarcoma. Proc Am Soc Clin Oncol 13:A20, 1994 (abstr)
14. Seidman A, Norton L, Reichman B, et al: Preliminary experience with paclitaxel plus recombinant human granulocyte colonystimulating factor in the treatment of breast cancer. Semin Oncol 20:40-45, 1993
15. Holmes F, Frye D, Valero V, et al: Phase I study of taxol and doxorubicin with G-CSF in patients without prior chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 11:66, 1992 (abstr)
16. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3 hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995
17. Citardi M, Rowinsky EK, Schafer KI, et al: Sequence-dependent cytotoxicity between cisplatin and the antimicrotubule agents Taxol and vincristine. Proc Am Assoc Cancer Res 31:2431, 1990 (abstr)
18. Forastiere A, Rowinsky E, Chaudry V, et al: Phase I trial of Taxol and cisplatin + G-CSF in solid tumors. Proc Am Soc Clin Oncol 11:289, 1992 (abstr)
19. McGuire WP, Hoskins WJ, Brady MF, et al: Taxol and cisplatin improves outcome in advanced ovarian cancer as compared to Cytoxan and cisplatin. Proc Am Soc Clin Oncol 12:255, 1995 (abstr)
20. Rowinsky E, Gilbert M, McGuire W, et al: Sequences of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991
21. Gelmon K: Biweekly paclitaxel in the treatment of patients with metastatic breast cancer. Semin Oncol 22:117-122, 1995
22. Reichman B, Seidman A, Crown J: Paclitaxel and recombinant human granulocyte colony stimulating factor as initial therapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
23. Seidman A, Tiersten C, Hudis C, et al: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13:2575-2581, 1995
24. Eisenhauer E, Huinink WtB, Swenerton K: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High dose versus low dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
25. Seidman AD, Hochhauser D, Yao T-J, et al: 96 hour paclitaxel after prior short taxane infusion: Phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. Proc Am Soc Clin Oncol 14:113, 1995 (abstr)
26. Mamounas E, Brown A, Fisher B, et al: 3 Hour high dose Taxol infusion in advanced breast cancer: An NSABP phase II study. Proc Am Soc Clin Oncol 14:127, 1995 (abstr)
27. Fennelly D, Gilewski T, Hudis C: Phase I trial of sequential edatrexate followed by paclitaxel: A design based on in vitro synergy in patients with advanced breast cancer. Proc Am Assoc Cancer Res 36:247, 1995 (abstr)
28. Ibrahim N, Hortobagyi G, Valero V: Phase I study of vinorelbine and paclitaxel by simultaneous 3 hour infusion for untreated metastatic breast cancer. Proc Am Assoc Cancer Res 36:242, 1995 (abstr)